An interventional study of canine mediation and standard psychomotor therapy in Epilepsy, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.
Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is the only one that started in 2026, is one of 3 with no phase, and was the 7th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18–65 · Healthy volunteers
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 6–18
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages up to 18
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 76 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 3 interventional studies, 50 across the 7 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
3 of the studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07075380Fondation Ophtalmologique Adolphe de RothschildNational Survey on Physical and Sports Activity of Adults With Epilepsy | 2027-05 |
| NCT04451278Fondation Ophtalmologique Adolphe de RothschildRESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy | 2027-10 |
| NCT07026591Fondation Ophtalmologique Adolphe de RothschildEpilepsy and Driving | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In addition to the search for new pharmaceutical or surgical solutions that could improve the therapeutic management of epileptic individuals, it is interesting to ask whether other complementary approaches, such as canine mediation in psychomotor therapy, could enhance the quality of life in this population.
However, there is currently no evidence indicating that exposure to animals through mediation sessions would be beneficial for epileptic individuals, particularly regarding their quality of life, anxiety, emotional management, or cognition (such as social cognition). In the absence of current data in this population, it seems pertinent to study the impact of this practice on people with epilepsy. Furthermore, beyond quality of life, it would be valuable to examine whether it also influences anxiety or the frequency of seizures in individuals with epilepsy (a phenomenon reported for epileptic individuals living with a pet dog or a service dog). Canine mediation could help better manage and regulate the emotions of epileptic individuals, as well as improve their self-esteem.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Difficult emotional and relational management And/or global motor difficulties And/or body schema organization disorder And/or temporo-spatial disorder
Exclusion Criteria:
Group psychomotor therapy sessions combined with canine mediation (1 session per week for 10 weeks)
Other: canine mediation
Standard group psychomotor therapy sessions (1 session per week for 10 weeks)
Other: standard psychomotor therapy
Animal mediation consists of bringing an animal into contact with a specific audience to improve the mental or physical health of a person. The dog and beneficiaries interact through various activities, in which the animal participates, offered during the sessions. The dog plays a particularly important role as a mediator through the bonds it forms with the human, as well as a non-judgmental partner in interaction. The canine educator will be accompanied by a healthcare professional during interventions. The sessions are organized based on the expertise and suggestions of both professions (canine educator and psychomotor therapist). The canine educator will be a state-certified professional educator with a specialization in animal mediation. The dog used is trained by the educator, with two types of learning being worked on: emotions and "commands" on cue.
standard sessions of psychomotor therapy
Improvement of quality of life
Increase in the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) score of at least 5 points between inclusion and one week after the completion of the 10 sessions. The score of the QOLIE-31 (Quality of Life in Epilepsy Inventory-31) ranges from 0 to 100. A score of 0 represents the worst possible quality of life, while a score of 100 represents the best possible quality of life.
Time frame: Day 0 and Day 7 after the end of the 10 sessions
Started Sep 2026 (actual). Primary completion is estimated for Mar 2030, 42 months after the start.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 42 months is close to that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Jan 2026 → Sep 2026, primary completion Jun 2029 → Mar 2030 and completion Jun 2029 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild →